Contributors : Nishanth Kandepedu
Date : Apr’25
Introduction
Protein degradation is an important process in the cell. It helps keep the cell healthy and functioning properly. Targeted protein degradation (TPD) is a new treatment that uses this process to eliminate harmful proteins related to diseases. Instead of only stopping a protein’s function, TPD focuses on completely removing it from the cell. This gives a powerful new approach to finding and developing drugs as part of modern drug discovery.
TPD changes the way proteins are balanced in cells. It guides the cell’s system that breaks down proteins to focus on specific proteins we want to treat. Small molecules assist in this process by moving the target protein closer to the cell’s tools for breaking proteins down.
What makes TPD special is that it can pay attention to more proteins than older methods, which just block them. This new way helps us discover treatments for diseases linked to proteins we couldn’t reach before. These proteins include key ones like transcription factors and scaffolding proteins.
The basics of protein degradation
The human body has smart ways to break down proteins and recycle them. This process helps keep our cells healthy. There are two main systems that do this work: the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway (ALP).
The UPS tags proteins using molecules known as ubiquitin. These tags inform the proteasome to locate and break down the identified protein.
The ALP works in a unique way. It takes in proteins through autophagosomes, which later merge with lysosomes where enzymes break down the proteins inside. Many targeted protein degradation (TPD) approaches focus on controlling either the UPS or the ALP to break down specific disease-causing proteins.
Importance in disease treatment and prevention
Targeted protein degradation might change how we treat and prevent diseases. Rather than just blocking harmful proteins, this method eliminates them entirely. This makes it a powerful option for conditions where traditional small-molecule drugs fall short.
TPD supports treatment strategies across cancer, immune disorders, and neurodegenerative diseases. Compared to conventional inhibitors, TPD approaches may reduce off-target toxicity and allow lower dosing.
Historical perspective on protein degradation
Although targeted protein degradation appears new, its roots trace back to discoveries in the 1970s and 1980s with the identification of the ubiquitin-proteasome system (UPS). These foundational insights revealed how cells regulate protein levels and laid the groundwork for modern TPD strategies.
Mechanisms of targeted protein degradation
Targeted protein degradation leverages natural cellular systems such as the UPS and ALP to remove specific proteins. By designing small molecule degraders, researchers can redirect these systems to eliminate disease-associated proteins.
Key technologies in targeted protein degradation
PROTACs – proteolysis targeting chimeras
PROTACs are bifunctional molecules composed of two ligands connected by a linker. One ligand binds the target protein, while the other binds an E3 ubiquitin ligase, forming a ternary complex that triggers ubiquitination and degradation.
PROTACs enable degradation of proteins previously considered undruggable and allow a single molecule to degrade multiple protein copies, increasing efficiency and potentially lowering required doses.
Molecular glues
Molecular glues bind to E3 ligases and induce new protein–protein interactions with neo-substrates. This expands the scope of targeted protein degradation to proteins lacking conventional binding pockets.
Hydrophobic tags
Hydrophobic tags attach hydrophobic moieties to target proteins, mimicking misfolded proteins and triggering chaperone-mediated degradation pathways. While promising, specificity remains an area of active research.
LYTACs – Lysosome targeting chimeras
LYTACs use the autophagy-lysosome pathway rather than the proteasome, enabling degradation of extracellular and membrane-bound proteins. This expands therapeutic possibilities beyond intracellular targets.
Advancements in drug discovery through TPD
Targeted protein degradation is transforming drug discovery by expanding the druggable proteome. It enables novel therapeutic strategies across oncology, immunology, and neurodegeneration, supporting data-driven drug discovery.
Future directions in targeted protein degradation
Future research aims to improve degrader selectivity, overcome resistance mechanisms, and enhance delivery strategies. Continued innovation will further integrate TPD into precision medicine pipelines.
Conclusion
Recent advances in targeted protein degradation, including PROTACs and molecular glues, are reshaping therapeutic strategies. These technologies show promise for treating solid tumors and hematological cancers, positioning TPD as a key driver of future precision medicine and targeted therapies.
Find out how Excelra’s GOSTAR can help your precision medicine projects and solve data-related challenges in drug discovery, pharmaceuticals, and healthcare.
